Compare Stocks: VNDA, SPTX, TBPH, and ANRO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANRO Alto Neuroscience	$22.03 +0.3%	$29.45	$10.20 ▼ $37.48	$864.30M	1.31	426,668 shs	550,062 shs
SPTX Seaport Therapeutics	$20.83 +1.1%	$21.53	$14.85 ▼ $28.38	$1.12B	N/A	219,420 shs	124,685 shs
TBPH Theravance Biopharma	$17.03	$17.03	$13.08 ▼ $21.03	$884.18M	0.25	680,323 shs	N/A
VNDA Vanda Pharmaceuticals	$3.94 -1.7%	$4.94	$3.88 ▼ $9.94	$238.21M	0.69	1.49 million shs	810,273 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANRO Alto Neuroscience	0.00%	-0.14%	-17.49%	-21.08%	+99.16%
SPTX Seaport Therapeutics	0.00%	+15.59%	-4.23%	+0.34%	+2,060,999,900.00%
TBPH Theravance Biopharma	0.00%	0.00%	0.00%	+1.01%	+19.26%
VNDA Vanda Pharmaceuticals	0.00%	-0.50%	-20.59%	-23.18%	-27.09%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANRO Alto Neuroscience	$22.03 +0.3%	$29.45	$10.20 ▼ $37.48	$864.30M	1.31	426,668 shs	550,062 shs
SPTX Seaport Therapeutics	$20.83 +1.1%	$21.53	$14.85 ▼ $28.38	$1.12B	N/A	219,420 shs	124,685 shs
TBPH Theravance Biopharma	$17.03	$17.03	$13.08 ▼ $21.03	$884.18M	0.25	680,323 shs	N/A
VNDA Vanda Pharmaceuticals	$3.94 -1.7%	$4.94	$3.88 ▼ $9.94	$238.21M	0.69	1.49 million shs	810,273 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANRO Alto Neuroscience	0.00%	-0.14%	-17.49%	-21.08%	+99.16%
SPTX Seaport Therapeutics	0.00%	+15.59%	-4.23%	+0.34%	+2,060,999,900.00%
TBPH Theravance Biopharma	0.00%	0.00%	0.00%	+1.01%	+19.26%
VNDA Vanda Pharmaceuticals	0.00%	-0.50%	-20.59%	-23.18%	-27.09%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANRO Alto Neuroscience	2.64	Moderate Buy	$37.88	71.96% Upside
SPTX Seaport Therapeutics	2.69	Moderate Buy	$37.25	78.83% Upside
TBPH Theravance Biopharma	2.00	Hold	$19.40	13.92% Upside
VNDA Vanda Pharmaceuticals	2.44	Hold	$13.08	232.06% Upside

Current Analyst Ratings Breakdown

Latest VNDA, SPTX, TBPH, and ANRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/19/2026	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$55.00 ➝ $60.00
10/15/2026	VNDA Vanda Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/14/2026	SPTX Seaport Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$28.00
10/8/2026	SPTX Seaport Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/8/2026	SPTX Seaport Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$50.00
10/6/2026	VNDA Vanda Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
10/5/2026	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$20.00
9/25/2026	SPTX Seaport Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D+) ➝ Sell (D)
9/25/2026	SPTX Seaport Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Strong-Buy	$46.00
9/25/2026	SPTX Seaport Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Strong-Buy	$46.00
9/24/2026	TBPH Theravance Biopharma	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Neutral

(Data available from 10/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	$4.87 per share	N/A
SPTX Seaport Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	$104.31M	8.48	N/A	N/A	$5.86 per share	2.91
VNDA Vanda Pharmaceuticals	$216.10M	1.10	N/A	N/A	$5.54 per share	0.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANRO Alto Neuroscience	-$63.24M	-$2.42	N/A	N/A	N/A	N/A	-46.46%	-39.09%	11/11/2026 (Estimated)
SPTX Seaport Therapeutics	-$74.88M	-$12.12	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	$105.89M	$1.01	16.86	21.02	N/A	51.58%	-0.77%	-0.46%	11/10/2026 (Estimated)
VNDA Vanda Pharmaceuticals	-$220.47M	-$4.63	N/A	N/A	N/A	-127.41%	-49.81%	-33.29%	10/28/2026 (Estimated)

Latest VNDA, SPTX, TBPH, and ANRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	ANRO Alto Neuroscience	-$0.6735	N/A	N/A	N/A	N/A	N/A
11/10/2026	Q3 2026	TBPH Theravance Biopharma	$0.24	N/A	N/A	N/A	$21.95 million	N/A
10/28/2026	Q3 2026	VNDA Vanda Pharmaceuticals	-$0.72	N/A	N/A	N/A	$69.20 million	N/A
8/12/2026	Q2 2026	ANRO Alto Neuroscience	-$0.7345	-$0.65	+$0.0845	-$0.65	N/A	N/A
8/10/2026	Q2 2026	TBPH Theravance Biopharma	$0.0725	-$0.11	-$0.1825	-$0.11	$22.49 million	$20.73 million
8/5/2026	Q2 2026	VNDA Vanda Pharmaceuticals	-$0.5825	-$1.04	-$0.4575	-$1.04	$61.93 million	$50.53 million
8/3/2026	Q2 2026	SPTX Seaport Therapeutics	-$0.71	-$1.78	-$1.07	-$1.78	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A
SPTX Seaport Therapeutics	N/A	N/A	N/A	N/A	N/A
TBPH Theravance Biopharma	N/A	N/A	N/A	N/A	N/A
VNDA Vanda Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANRO Alto Neuroscience	0.07	14.85	14.85
SPTX Seaport Therapeutics	N/A	18.00	18.00
TBPH Theravance Biopharma	N/A	13.54	13.54
VNDA Vanda Pharmaceuticals	0.01	1.61	1.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANRO Alto Neuroscience	N/A
SPTX Seaport Therapeutics	N/A
TBPH Theravance Biopharma	99.10%
VNDA Vanda Pharmaceuticals	88.14%

Insider Ownership

Company	Insider Ownership
ANRO Alto Neuroscience	11.25%
SPTX Seaport Therapeutics	N/A
TBPH Theravance Biopharma	7.65%
VNDA Vanda Pharmaceuticals	10.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANRO Alto Neuroscience	68	39.24 million	34.83 million	Optionable
SPTX Seaport Therapeutics	58	53.53 million	N/A	N/A
TBPH Theravance Biopharma	110	51.92 million	47.95 million	Optionable
VNDA Vanda Pharmaceuticals	533	60.46 million	53.99 million	Optionable

VNDA, SPTX, TBPH, and ANRO Headlines

Recent News About These Companies

Vanda Pharmaceuticals (VNDA) Set to Post Earnings on Wednesday

October 23 at 2:10 AM | americanbankingnews.com

Vanda Pharmaceuticals (VNDA) Projected to Release Quarterly Earnings on Wednesday

October 23 at 2:10 AM | marketbeat.com

Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026

October 21, 2026 | prnewswire.com

Vanda puts VQW-765 on hold: Vanda Pharmaceuticals stock costs EUR 3.64

October 21, 2026 | ad-hoc-news.deA

Vanda puts VQW-765 on hold: what it means for Vanda Pharmaceuticals stock

October 18, 2026 | ad-hoc-news.deA

Vanda Pharmaceuticals: Cash Is Running Out Faster Than The Launches

October 15, 2026 | seekingalpha.com

Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program

October 15, 2026 | finanznachrichten.de

Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary Endpoint

October 15, 2026 | benzinga.com

Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary Endpoint

October 15, 2026 | benzinga.com

Vanda Pharmaceuticals stock falls after anxiety drug trial fails

October 14, 2026 | finance.yahoo.com

Vanda Pharmaceuticals' Late-Stage Study of VQW-765 to Treat Acute Anxiety Fails to Meet Primary Endpoint

October 14, 2026 | finance.yahoo.com

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

October 14, 2026 | reuters.com

Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program

October 14, 2026 | prnewswire.com

Vanda’s Tasimelteon Study Completion: What Sleep Trial Progress Means for VNDA Investors

October 9, 2026 | tipranks.com

Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Rating Lowered by Zacks Research

October 8, 2026 | marketbeat.com

Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Rating Reaffirmed as Buy by HC Wainwright

October 5, 2026 | marketbeat.com

Vanda Pharmaceuticals: Buy Rating Reaffirmed as HETLIOZ Phase 3 Success in DSWPD Supports sNDA; $20 Price Target Maintained

October 5, 2026 | tipranks.com

Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting

October 2, 2026 | prnewswire.com

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Consensus Rating of "Moderate Buy" from Analysts

October 2, 2026 | marketbeat.com

Vanda: 'Hold' On Hetlioz Trial Win, But Several Risk Factors Remain For It

October 1, 2026 | seekingalpha.com

VNDA Stock Fades After Hetlioz Sleep-Trial Win — Here’s Why

September 30, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNDA, SPTX, TBPH, and ANRO Company Descriptions

Alto Neuroscience NYSE:ANRO

$22.03 +0.06 (+0.25%)

Closing price 03:59 PM Eastern

Extended Trading

$22.10 +0.07 (+0.31%)

As of 04:10 PM Eastern

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Seaport Therapeutics NASDAQ:SPTX

$20.83 +0.22 (+1.07%)

As of 04:00 PM Eastern

Seaport Therapeutics Inc. is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc. is based in BOSTON.

Theravance Biopharma NASDAQ:TBPH

$17.03 0.00 (0.00%)

As of 10/23/2026

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

Vanda Pharmaceuticals NASDAQ:VNDA

$3.94 -0.07 (-1.75%)

Closing price 04:00 PM Eastern

Extended Trading

$3.94 +0.00 (+0.13%)

As of 04:16 PM Eastern

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VNDA, SPTX, TBPH, and ANRO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VNDA, SPTX, TBPH, and ANRO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VNDA, SPTX, TBPH, and ANRO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNDA, SPTX, TBPH, and ANRO Company Descriptions

Alto Neuroscience NYSE:ANRO

Seaport Therapeutics NASDAQ:SPTX

Theravance Biopharma NASDAQ:TBPH

Vanda Pharmaceuticals NASDAQ:VNDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VNDA, SPTX, TBPH, and ANRO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VNDA, SPTX, TBPH, and ANRO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VNDA, SPTX, TBPH, and ANRO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNDA, SPTX, TBPH, and ANRO Company Descriptions

Alto Neuroscience NYSE:ANRO

Seaport Therapeutics NASDAQ:SPTX

Theravance Biopharma NASDAQ:TBPH

Vanda Pharmaceuticals NASDAQ:VNDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools